Early Aggressive Treatment of Acral Vitiligo to Prevent Psychosocial Trauma

Conclusions

• Acral vitiligo on the hands and especially the fingertips is much harder to repigment than facial or trunk vitiligo because of lower melanocyte reserves and less follicular repopulation.
• Vitiligo appears to be driven by both immune attack and melanocyte dysfunction, so treatment must address both the inflammatory process and melanocyte recovery.
• The JAK-STAT pathway is a central therapeutic target in vitiligo, and JAK inhibitors are likely to expand treatment options further.
• Early localized or unstable vitiligo should be treated quickly and aggressively because early intervention can stabilize disease, improve repigmentation, and reduce recurrence.
• Combination therapy with phototherapy plus systemic or topical anti-inflammatory treatment can produce meaningful repigmentation, even in difficult hand disease, if started early enough.
• Once depigmentation reaches the digital tips, repigmentation is unlikely, making prevention of progression more important than late rescue.
• Segmental vitiligo is often more amenable to localized treatment and, when stable, may respond well to surgical approaches if medical therapy fails.
• Vitiligo has major psychosocial consequences, with visible hand and facial lesions strongly linked to depression and reduced quality of life.
• Treatment decisions should be guided not only by body surface area but also by lesion location, disease activity, and psychosocial burden.
• The field is improving for most vitiligo sites, but the fingertips remain the greatest unmet need and will likely be the last area to respond well to current therapies.